News

Qiagen steps into NGS market
Enlarge image

BusinessGermanyNetherlands

Qiagen steps into NGS market

22.02.2013 - Molecular diagnostics and lab provider Qiagen is entering the highly competitive market of Next-Generation Sequencing (NGS) benchtop sequencers.

The company presented a sample-to-result Next-Generation Sequencing workflow designed for clinical research and diagnostics at the AGBT meeting in Florida. However, its sample preparation, newly introduced benchtop sequencer GeneReaderTM and bioinformatics solution is for research use only, as those are of its competitors Roche, Illumina and Life Technologies. However, the announcement suggested that the Dutch-German company’s NGS workflow is automated from primary sample to digital result.

"Next-generation sequencing is making a transformational impact on life science, but challenges are limiting more widespread adoption for clinical purposes," said Peer M. Schatz, CEO of QIAGEN. "The development of our complete sample-to-result workflow is a key achievement in our initiative to offer a seamless integration of new NGS platforms with high-quality reagents, molecular testing content and services."

No sequencing firm currently has a NGS workflow that is simple and reliable enough for diagnostic purposes. However, all of them aim at establishing highly automated and inter-laboratory reproducible NGS procedures that can be used by non-specialists. The adoption of NGS in fields such as clinical research and diagnostics is still hampered by workflow challenges, manual sample preparation processes, the speed, comparability and quality of data analysis.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/qiagen-steps-into-ngs-market.html

EbolaEUFrance

30.09.2014 In the face of the Ebola outbreak sweeping the West African countries, the EMA has started to review investigational treatments for the deadly virus disease.

FinancingSwitzerlandGermanyNetherlandsFrance

26.09.2014 Biotechnology has made the news in the stock market this month, as a wave of companies announced plans to launch IPOs on European exchanges later this year.

ResearchGermany

25.09.2014 After being hit hard by the Andromeda trial data falsification scandal, German biotech Evotec is moving back into calmer waters with new MS research projects.

FinancingNetherlands

23.09.2014 Dutch Biotech VC firm Aglaia has launched a new US$65m fund targeted towards biotechnology startups working on groundbreaking technologies aimed at preventing and curing cancer.

BusinessGermany

19.09.2014 In order to concentrate on the life science business, German industry giant Bayer is splitting off its plastics subgroup as a separate company.

FinanceSwitzerland

18.09.2014 Swiss biopharma Cardiorentis has received a €45m investment from overseas investment firm Healthcare Royalty Partners in order to finance the registration for its heart drug.

PoliticsEU

15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CO.DON3.13 EUR5.03%
  • 4SC1.06 EUR3.92%
  • SANTHERA88.65 CHF2.78%

FLOP

  • CYTOS0.19 CHF-9.52%
  • WILEX2.13 EUR-6.99%
  • FORMYCON8.03 EUR-5.42%

TOP

  • PAION3.18 EUR30.9%
  • CO.DON3.13 EUR26.2%
  • FORMYCON8.03 EUR17.7%

FLOP

  • CYTOS0.19 CHF-24.0%
  • ADDEX3.13 CHF-21.4%
  • EVOTEC3.06 EUR-18.2%

TOP

  • SANTHERA88.65 CHF2088.9%
  • PAION3.18 EUR238.3%
  • CO.DON3.13 EUR229.5%

FLOP

  • CYTOS0.19 CHF-95.1%
  • 4SC1.06 EUR-45.4%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 29.09.2014